106 related articles for article (PubMed ID: 11145989)
1. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease.
Morton AJ; Edwardson JM
J Neurochem; 2001 Jan; 76(1):166-72. PubMed ID: 11145989
[TBL] [Abstract][Full Text] [Related]
2. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease.
Morton AJ; Faull RL; Edwardson JM
Brain Res Bull; 2001 Sep; 56(2):111-7. PubMed ID: 11704347
[TBL] [Abstract][Full Text] [Related]
3. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.
Freeman W; Morton AJ
Brain Res Bull; 2004 Mar; 63(1):45-55. PubMed ID: 15121238
[TBL] [Abstract][Full Text] [Related]
4. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
Smith R; Petersén A; Bates GP; Brundin P; Li JY
Neurobiol Dis; 2005 Dec; 20(3):673-84. PubMed ID: 15967669
[TBL] [Abstract][Full Text] [Related]
5. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
6. Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II.
Edwardson JM; Wang CT; Gong B; Wyttenbach A; Bai J; Jackson MB; Chapman ER; Morton AJ
J Biol Chem; 2003 Aug; 278(33):30849-53. PubMed ID: 12807877
[TBL] [Abstract][Full Text] [Related]
7. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation.
Morton AJ; Lagan MA; Skepper JN; Dunnett SB
J Neurocytol; 2000 Sep; 29(9):679-702. PubMed ID: 11353291
[TBL] [Abstract][Full Text] [Related]
8. Signature changes in ubiquilin expression in the R6/2 mouse model of Huntington's disease.
Safren N; Chang L; Dziki KM; Monteiro MJ
Brain Res; 2015 Feb; 1597():37-46. PubMed ID: 25511991
[TBL] [Abstract][Full Text] [Related]
9. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
[TBL] [Abstract][Full Text] [Related]
10. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.
Milnerwood AJ; Cummings DM; Dallérac GM; Brown JY; Vatsavayai SC; Hirst MC; Rezaie P; Murphy KP
Hum Mol Genet; 2006 May; 15(10):1690-703. PubMed ID: 16600988
[TBL] [Abstract][Full Text] [Related]
11. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse.
Gibson HE; Reim K; Brose N; Morton AJ; Jones S
Eur J Neurosci; 2005 Oct; 22(7):1701-12. PubMed ID: 16197510
[TBL] [Abstract][Full Text] [Related]
12. Interaction of huntingtin fragments with brain membranes--clues to early dysfunction in Huntington's disease.
Suopanki J; Götz C; Lutsch G; Schiller J; Harjes P; Herrmann A; Wanker EE
J Neurochem; 2006 Feb; 96(3):870-84. PubMed ID: 16405500
[TBL] [Abstract][Full Text] [Related]
13. Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease.
Smith R; Klein P; Koc-Schmitz Y; Waldvogel HJ; Faull RL; Brundin P; Plomann M; Li JY
J Neurochem; 2007 Oct; 103(1):115-23. PubMed ID: 17877635
[TBL] [Abstract][Full Text] [Related]
14. Early, transient increase in complexin I and complexin II in the cerebral cortex following traumatic brain injury is attenuated by N-acetylcysteine.
Yi JH; Hoover R; McIntosh TK; Hazell AS
J Neurotrauma; 2006 Jan; 23(1):86-96. PubMed ID: 16430375
[TBL] [Abstract][Full Text] [Related]
15. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
Hickey MA; Reynolds GP; Morton AJ
J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
[TBL] [Abstract][Full Text] [Related]
16. Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions.
Khedraki A; Reed EJ; Romer SH; Wang Q; Romine W; Rich MM; Talmadge RJ; Voss AA
J Neurosci; 2017 Aug; 37(34):8077-8091. PubMed ID: 28724748
[TBL] [Abstract][Full Text] [Related]
17. A complexin/synaptotagmin 1 switch controls fast synaptic vesicle exocytosis.
Tang J; Maximov A; Shin OH; Dai H; Rizo J; Südhof TC
Cell; 2006 Sep; 126(6):1175-87. PubMed ID: 16990140
[TBL] [Abstract][Full Text] [Related]
18. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
Dufour BD; McBride JL
Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
[TBL] [Abstract][Full Text] [Related]
19. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
Wade A; Jacobs P; Morton AJ
Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
[TBL] [Abstract][Full Text] [Related]
20. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
